Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7GSLB)

Drug Name
SC-20713 Drug Info
Synonyms
Etynodiol; Aethynodiolum; CHEBI:50785; CHEMBL1201406; DB13866; DTXSID1023025; EINECS 214-971-5; Ethinodiol; Etinodiol; Etinodiol [INN-Spanish]; Etinodiolo; Etinodiolo [DCIT]; Etynodiol (INN); Etynodiol [INN:BAN]; Etynodiolum; Etynodiolum [INN-Latin]; HSDB 7897; LS-97401; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol; (3beta,17alpha)-19-Norpregn-4-en-20-yne-3,17-diol; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diol; 1231-93-2; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol; 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17beta-diol; 17alpha-Ethynyl-estra-4-ene-3beta,17beta-diol; 17alpha-ethynylestr-4-ene-3beta,17beta-diol; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol; 3beta-hydroxynorethisterone; 9E01C36A9S; SCHEMBL140933; UNII-9E01C36A9S; ZINC30691629; ethynodiol; ZINC000030691629
Cross-matching ID
PubChem CID
14309340
CAS Number
CAS 1231-93-2
INTEDE Drug ID
DR0673

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Maturity onset diabetes of the young 2.01 8.38e-3 21/26 (80.77%) PAX6;NKX2-2;HHEX;...
Coronavirus disease -1.63 3.59e-2 215/232 (92.67%) TLR8;RPS21;RPL22;...
Th1 and Th2 cell differentiation -1.64 3.65e-2 80/92 (86.96%) JAK2;HLA-DRB1;JAG2;...
Complement and coagulation cascades -1.64 3.78e-2 76/85 (89.41%) CFHR4;CD46;CFH;...
Intestinal immune network for IgA production -1.66 3.54e-2 38/48 (79.17%) ICOS;TNFSF13;CCR9;...
Rheumatoid arthritis -1.67 3.34e-2 78/93 (83.87%) TGFB3;ITGAL;CTSK;...
Cell adhesion molecules -1.67 3.48e-2 118/148 (79.73%) CD80;CTLA4;NRXN1;...
Cytokine-cytokine receptor interaction -1.68 3.63e-2 246/295 (83.39%) LTB;CXCR4;TNFSF18;...
African trypanosomiasis -1.68 3.72e-2 32/37 (86.49%) IFNG;PLCB1;HBB;...
Natural killer cell mediated cytotoxicity -1.70 2.76e-2 99/131 (75.57%) PRKCA;SYK;FASLG;...
Antigen processing and presentation -1.71 2.80e-2 60/78 (76.92%) PSME3;KLRC3;HLA-C;...
Proteasome -1.73 2.32e-2 44/46 (95.65%) PSMA2;PSME3;PSMD11;...
Type I diabetes mellitus -1.74 2.32e-2 38/43 (88.37%) IL12B;CD80;FASLG;...
Pertussis -1.77 1.67e-2 64/76 (84.21%) ITGA5;CASP3;MAPK14;...
Tyrosine metabolism -1.79 1.59e-2 30/36 (83.33%) HPD;MIF;ADH1B;...
Asthma -1.79 1.82e-2 25/31 (80.65%) HLA-DRB1;CCL11;HLA-DPB1;...
Autoimmune thyroid disease -1.89 5.79e-3 46/53 (86.79%) TSHB;CD80;CTLA4;...
Viral protein interaction with cytokine and cytokine re... -2.09 0.00e+0 84/100 (84%) CXCR4;CCL18;CCR10;...
Graft-versus-host disease -2.17 0.00e+0 32/42 (76.19%) CD80;FASLG;HLA-C;...
Allograft rejection -2.19 0.00e+0 32/38 (84.21%) IL12B;CD80;FASLG;...
Staphylococcus aureus infection -2.21 0.00e+0 72/95 (75.79%) C3;KRT10;HLA-DRB1;...
Systemic lupus erythematosus -2.39 0.00e+0 45/135 (33.33%) SSB;C3;HLA-DRB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H